Skip to content

PRELIMINARY EFFECTS OF A MULTI-COMPONENT SYNERGISTIC SYNBIOTICS FORMULA ON MODERATE ANXIETY IN THAI MIDDLE-AGED WOMEN: A RANDOMIZED, PLACEBO-CONTROLLED PILOT TRIAL

Preliminary effects of a multi-component synergistic synbiotics formula on moderate anxiety in Thai middle-aged women: A randomized, placebo-controlled pilot trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260202003
Enrollment
36
Registered
2026-02-02
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate Anxiety Perimenopause Psychological Stress Sleep Quality Synbiotics Anxiety Perimenopause Psychobiotics Middle Aged Women Gut Brain Axis

Interventions

MOOD PRO MS Dietary Supplement Product JHAMJUN Brand Powder form 2g sachet containing Probiotics Lactobacillus helveticus and Bifidobacterium longum Prebiotic GOS and synergistic nutrients Vit B compl
MOOD PRO MS,Placebo

Sponsors

Dhurakij Pundit University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Thai female, aged 40-50 years. 2. In perimenopausal stage (early or late transition). 3. Having moderate anxiety (GAD-7 score of 10-14). 4. Voluntary participation and signed informed consent. 5. Able to comply with study procedures for 4 weeks. 6. Able to access and use the internet for online assessments.

Exclusion criteria

Exclusion criteria: 1. History of hysterectomy and/or bilateral oophorectomy. 2. Pregnant or breastfeeding. 3. Currently receiving hormone replacement therapy (HRT) or hormonal contraceptives. 4. Currently using antidepressants, anxiolytics, hypnotics, or other psychiatric medications. 5. Use of antibiotics within 1 month prior to screening. 6. Regular consumption of probiotic or synbiotic products within 1 month prior to screening. 7. Diagnosis of severe psychiatric disorders (e.g., major depression, bipolar disorder, suicide risk). 8. Alcohol or substance abuse. 9. Uncontrolled chronic diseases, autoimmune diseases, or severe gastrointestinal diseases. 10. History of allergy to lactic acid bacteria. 11. BMI less than 18.5 or greater than 30.0 kg/m2. 12. Current smoker or consumes alcohol > 3 times/week. 13. Shift worker affecting sleep patterns.

Design outcomes

Primary

MeasureTime frame
Change in Anxiety Level Baseline and Week 4 Generalized Anxiety Disorder-7 (GAD-7) scale score.

Secondary

MeasureTime frame
Stress Level Baseline and Week 4 Perceived Stress Scale-10 (PSS-10) score.,Sleep Quality Baseline and Week 4 Pittsburgh Sleep Quality Index (PSQI) score.,Safety and Tolerability Throughout the 4-week study period Incidence and severity of adverse events (AEs), especially gastrointestinal symptoms.,Change in Dietary Patterns Baseline and Week 4 Food Frequency Questionnaire (FFQ) score.,Change in Physical Activity Level Baseline and Week 4 International Physical Activity Questionnaire (IPAQ) score.

Countries

Thailand

Contacts

Public ContactParichat Wongpuk

Dhurakij Pundit University

parichatwognpuk@gmail.com0925131489

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026